Themis Medicare Limited has informed the Exchange regarding Board meeting held on August 01, 2025.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Themis Medicare's Board approved its Q1 FY26 (quarter ended 30 June 2025) unaudited financial results, showing revenue from operations of ₹9,757.77 lakhs, down about 21% from ₹12,299.38 lakhs in the same quarter last year. The company swung from a profit of ₹1,871.47 lakhs (Q1 FY25) to a loss of ₹1,537.37 lakhs, with an exceptional charge of ₹129.39 lakhs related to the strike-off of its UK subsidiary Carpo Medicals Limited. The Board also appointed Ms. Neha Thakore as an Additional Non-Executive Woman Independent Director for 5 years and Mr. Viraj Save as Executive President – Sales & Marketing. Additionally, the proposed merger with Gujarat Themis Biosyn Limited (GTBL) has been withdrawn by mutual decision, with Themis refocusing on its domestic formulations business.
Weak quarterly performance with a sharp revenue drop and a swing to a loss is negative for near-term sentiment, though the loss partly stems from one-time items. The withdrawn GTBL merger removes a potential growth catalyst, while the dividend record date (5 Sept 2025) signals a final dividend payout for FY25 shareholders.